Related references
Note: Only part of the references are listed.Anti-HER2 therapy in metastatic breast cancer: many choices and future directions
Carrie S. Wynn et al.
CANCER AND METASTASIS REVIEWS (2022)
The role of membrane mucin MUC4 in breast cancer metastasis
Courtney A. Dreyer et al.
ENDOCRINE-RELATED CANCER (2022)
Systemic Therapy for Advanced Human 3 Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Guideline Update
Sharon H. Giordano et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Src activation in lipid rafts confers epithelial cells with invasive potential to escape from apical extrusion during cell competition
Kentaro Kajiwara et al.
CURRENT BIOLOGY (2022)
CD200 ectodomain shedding into the tumor microenvironment leads to NK cell dysfunction and apoptosis
Huw J. Morgan et al.
JOURNAL OF CLINICAL INVESTIGATION (2022)
LncRNALINC00467acted as an oncogene in esophageal squamous cell carcinoma by accelerating cell proliferation and preventing cell apoptosis via themiR-485-5p/DPAGT1axis
Zhenghua Liu et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2021)
Endoplasmic reticulum-associated degradation is required for nephrin maturation and kidney glomerular filtration function
Sei Yoshida et al.
JOURNAL OF CLINICAL INVESTIGATION (2021)
HER2-targeted therapies - a role beyond breast cancer
Do-Youn Oh et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
Targeting ADAM10 in Cancer and Autoimmunity
Timothy M. Smith et al.
FRONTIERS IN IMMUNOLOGY (2020)
DPAGT1 Inhibitors of Capuramycin Analogues and Their Antimigratory Activities of Solid Tumors
Katsuhiko Mitachi et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Structure-based drug discovery by targeting N-glycan biosynthesis, dolichyl-phosphate N-acetylglucosaminephosphotransferase
Michio Kurosu
FUTURE MEDICINAL CHEMISTRY (2019)
Semisynthesis of an Anticancer DPAGT1 Inhibitor from a Muraymycin Biosynthetic Intermediate
Katsuhiko Mitachi et al.
ORGANIC LETTERS (2019)
Breast cancer statistics, 2019
Carol E. DeSantis et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
A practical synthesis of a novel DPAGT1 inhibitor, aminouridyl phenoxypiperidinbenzyl butanamide (APPB) for in vivo studies
Katsuhiko Mitachi et al.
METHODSX (2019)
Structural and mechanistic aspects influencing the ADAM10-mediated shedding of the prion protein
Luise Linsenmeier et al.
MOLECULAR NEURODEGENERATION (2018)
GlcNAc-l-P-transferase-tunicamycin complex structure reveals basis for inhibition of N-glycosylation
Jiho Yoo et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2018)
GlcNAc-l-P-transferase-tunicamycin complex structure reveals basis for inhibition of N-glycosylation
Jiho Yoo et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2018)
Structures of DPAGT1 Explain Glycosylation Disease Mechanisms and Advance TB Antibiotic Design
Yin Yao Dong et al.
CELL (2018)
Molecular Pathways: Receptor Ectodomain Shedding in Treatment, Resistance, and Monitoring of Cancer
Miles A. Miller et al.
CLINICAL CANCER RESEARCH (2017)
BOK Is a Non-canonical BCL-2 Family Effector of Apoptosis Regulated by ER-Associated Degradation
Fabien Llambi et al.
CELL (2016)
ADAM10: a new player in breast cancer progression?
Maeve Mullooly et al.
BRITISH JOURNAL OF CANCER (2015)
Predictive value of serum HER2 ECD in patients with HER2-positive advanced gastric cancer treated with trastuzumab plus chemotherapy
Jun Zhou et al.
JOURNAL OF GASTROENTEROLOGY (2015)
Interaction of CDCP1 with HER2 Enhances HER2-Driven Tumorigenesis and Promotes Trastuzumab Resistance in Breast Cancer
Abdullah Alajati et al.
CELL REPORTS (2015)
Evaluation of serum HER2-ECD levels in patients with gastric cancer
Katsunobu Oyama et al.
JOURNAL OF GASTROENTEROLOGY (2015)
Src, a potential target for overcoming trastuzumab resistance in HER2-positive breast carcinoma
G. Peiro et al.
BRITISH JOURNAL OF CANCER (2014)
Quantitative Measurements of Tumoral p95HER2 Protein Expression in Metastatic Breast Cancer Patients Treated with Trastuzumab: Independent Validation of the p95HER2 Clinical Cutoff
Renata Duchnowska et al.
CLINICAL CANCER RESEARCH (2014)
N-Glycosylation Is Required for Matriptase-2 Autoactivation and Ectodomain Shedding
Jiang Jiang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
N-Glycosylation Regulates ADAM8 Processing and Activation
Srimathi Srinivasan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
The Mysterious Ways of ErbB2/HER2 Trafficking
Vibeke Bertelsen et al.
MEMBRANES (2014)
Gain of glycosylation in integrin α3 causes lung disease and nephrotic syndrome
Nayia Nicolaou et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks
Cole Trapnell et al.
NATURE PROTOCOLS (2012)
Aberrant amplification of the crosstalk between canonical Wnt signaling and N-glycosylation gene DPAGT1 promotes oral cancer
Basem Jamal et al.
ORAL ONCOLOGY (2012)
Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab
P. Todeschini et al.
BRITISH JOURNAL OF CANCER (2011)
Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways
Siyuan Zhang et al.
NATURE MEDICINE (2011)
Road to Ruin: Targeting Proteins for Degradation in the Endoplasmic Reticulum
Melanie H. Smith et al.
SCIENCE (2011)
Quantitation of p95HER2 in Paraffin Sections by Using a p95-Specific Antibody and Correlation with Outcome in a Cohort of Trastuzumab-Treated Breast Cancer Patients
Jeff Sperinde et al.
CLINICAL CANCER RESEARCH (2010)
N-Glycans of ADAMTS13 modulate its secretion and von Willebrand factor cleaving activity
Wenhua Zhou et al.
BLOOD (2009)
Overexpression of DPAGT1 Leads to Aberrant N-Glycosylation of E-Cadherin and Cellular Discohesion in Oral Cancer
Mihai Nita-Lazar et al.
CANCER RESEARCH (2009)
Evaluation of serum HER2 extracellular domain in early breast cancer patients:: correlation with clinicopathological parameters and survival
V. Ludovini et al.
ANNALS OF ONCOLOGY (2008)
Protein Kinases: Starting a Molecular Systems View of Endocytosis
Pisca Liberali et al.
ANNUAL REVIEW OF CELL AND DEVELOPMENTAL BIOLOGY (2008)
Functional role of N-glycosylation from ADAM10 in processing, localization and activity of the enzyme
Cristina Escrevente et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS (2008)
Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer
Suhail M. Ali et al.
CANCER (2008)
Tyrosine phosphorylation-dependence of caveolae-mediated endocytosis
Maria Sverdlov et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2007)
Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer
Maurizio Scaltriti et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Identification of ADAM10 as a major source of HER2 ectodomain sheddase activity in HER2 overexpressing breast cancer cells
Phillip C. C. Liu et al.
CANCER BIOLOGY & THERAPY (2006)
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
EH Romond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Herceptin-induced inhibition of ErbB2 signaling involves reduced phosphorylation of Akt but not endocytic down-regulation of ErbB2
KE Longva et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Genome-wide analysis of human kinases in clathrin- and caveolae/raft-mediated endocytosis
L Pelkmans et al.
NATURE (2005)
Adams: Key components in EGFR signalling and development
CP Blobel
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2005)
The regulation of endocytosis by kinases: cell biology meets genomics
Zita Balklava et al.
GENOME BIOLOGY (2005)
Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin
CD Austin et al.
MOLECULAR BIOLOGY OF THE CELL (2004)
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer
CL Vogel et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
A conserved ubiquitin ligase of the nuclear envelope/endoplasmic reticulum that functions in both ER-associated and Matα2 repressor degradation
R Swanson et al.
GENES & DEVELOPMENT (2001)
Regulation of the α-secretase ADAM10 by its prodomain and proprotein convertases
A Anders et al.
FASEB JOURNAL (2001)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Hrd1p/Der3p is a membrane-anchored ubiquitin ligase required for ER-associated degradation
NW Bays et al.
NATURE CELL BIOLOGY (2001)
HER2/Neu: mechanisms of dimerization/oligomerization
PJ Brennan et al.
ONCOGENE (2000)
Share Paper
